Natco Pharma Ltd (NATCOPHARM)
₹921.45
Mkt cap
₹16,504 Cr
P/E ratio
11.60
P/B
1.79
Div yield
0.65%
ROE
16.90%
ROCE
17.10%
EPS (TTM)
₹79.44
Book value
₹515
52W range
793–1,206
Sector
Healthcare
NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. [1] NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business. [2]
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−23.59% from high₹921
₹793+16.21% from low₹1,206
Current
₹921.45
Prev close
₹925.00
Day
−0.38%
Price performance
1D
−0.38%
1W
−3.07%
1M
+1.96%
3M
−15.71%
6M
+12.00%
1Y
−10.78%
YTD
+3.18%
Financials
FRevenue, profit & margin
P/E ratio
11.6×
NATCOPHARM is 66% below the sector median of 34.0×
NATCOPHARM11.6×
Sector median34.0×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 898 | 1,140 | 1,031 | 759 | 1,068 | 1,363 | 1,371 | 475 | 1,221 | 1,329 | 1,363 | 647 | 739 | |
| Expenses | 559 | 612 | 573 | 490 | 571 | 558 | 567 | 436 | 673 | 758 | 784 | 489 | 612 | |
| Operating Profit | 339 | 528 | 458 | 268 | 497 | 805 | 804 | 39 | 548 | 571 | 579 | 159 | 128 | |
| OPM % | 38% | 46% | 44% | 35% | 47% | 59% | 59% | 8% | 45% | 43% | 42% | 25% | 17% | |
| Other Income | 29 | 20 | 29 | 37 | 42 | 48 | 64 | 176 | 66 | 62 | 100 | 58 | 78 | |
| Interest | 3 | 4 | 4 | 5 | 6 | 5 | 4 | 4 | 10 | 3 | 13 | 10 | 11 | |
| Depreciation | 41 | 44 | 44 | 44 | 56 | 44 | 46 | 47 | 98 | 58 | 52 | 46 | 50 | |
| Profit before tax | 324 | 500 | 440 | 256 | 478 | 804 | 818 | 164 | 506 | 572 | 614 | 161 | 144 | |
| Tax % | 15% | 16% | 16% | 17% | 19% | 17% | 17% | 19% | 20% | 16% | 16% | 13% | -62% | |
| Net Profit | 276 | 420 | 369 | 213 | 386 | 668 | 676 | 132 | 406 | 480 | 518 | 151 | 269 | |
| EPS in Rs | 15.11 | 23.47 | 20.60 | 11.88 | 21.57 | 37.32 | 37.81 | 7.43 | 22.70 | 26.84 | 28.94 | 8.46 | 14.96 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.07% · closed higher next day 26 of last 58
| Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 9 Aug '23◦ | 14 Nov '23◦ | 14 Feb '24◦ | 27 May '24◦ | 12 Aug '24◦ | 12 Nov '24◦ | 12 Feb '25◦ | 28 May '25◦ | 12 Aug '25 | 14 Nov '25◦ | 12 Feb '26 | 29 May '26 |
| Earnings day | −1.97% | −4.48% | +0.26% | +0.28% | −1.30% | −1.72% | −20.00% | +3.64% | −1.28% | +1.02% | −1.29% | −13.60% |
| +1 day | −5.08% | −2.63% | +16.01% | +1.15% | −2.38% | −1.03% | −27.54% | +2.45% | +0.49% | +0.23% | −3.17% | −20.62% |
| +5 days | −3.21% | +0.67% | +14.03% | −5.74% | −1.51% | −2.39% | −34.92% | −0.06% | −1.22% | +3.52% | +4.41% | −24.02% |
| +15 days | +1.00% | −1.48% | +14.76% | +13.90% | +4.15% | +4.25% | −32.31% | +2.24% | −4.92% | +10.47% | +19.85% | −24.39% |
| +30 days | −5.05% | +2.15% | +12.94% | +15.02% | −5.23% | +0.47% | −33.96% | +15.77% | −6.39% | +10.41% | +14.50% | −16.66% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Interim Dividend - Rs 1.50 Per Share | 1.50 | 18 Feb '26 | 18 Feb '26 |
Shareholding
Sas of Jun 202649.41%Promoter
Promoters49.41%
FIIs16.99%0.38
DIIs5.63%0.17
Public27.97%0.23
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Natco Pharma | ₹921.45 | 11.63 | 16,504 | 0.65% | 269 | −34.11% | 739 | −39.47% | 17.14% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports15
Financial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2013nseFinancial Year 2012bse
Concall transcripts96
TranscriptJun 2026PPTJun 2026RECJun 2026TranscriptFeb 2026RECFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptJul 2025PPTJul 2025TranscriptJun 2025PPTJun 2025RECJun 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025RECJan 2025TranscriptNov 2024PPTNov 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Press Release / Media Release 18 Jul - NATCO received tentative FDA approval for Olaparib tablets on July 18, 2026; litigation remains ongoing.Announcement under Regulation 30 (LODR)-Press Release / Media Release 14 Jul - Natco Pharma completed 13.25% stake acquisition in Adcock Ingram for about ₹1,060 crore, lifting holding to 49%.Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order 14 Jul - APGST/CGST order dated 13 July 2026 raises ₹21.35 lakh tax, ₹17.18 lakh interest and ₹21.35 lakh penalty.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 JulBoard Meeting Outcome for Outcome Of Board Meeting 8 Jul - Board approved up to ₹1,400 crore investment and 49% stake acquisition in Adcock Ingram.